Shanghai RAAS Blood Products (002252.SZ): SR604 injection enters phase II clinical trial research.

Shanghai RAAS Blood Products (002252.SZ) announced that the company recently disclosed the registration information for the phase II clinical trial of "SR604 Injection" on the Drug Clinical Trial Registration and Information Disclosure Platform of the National Medical Products Administration. The trial is named: Evaluation of the safety, tolerability, efficacy, and PK/PD characteristics of SR604 Injection in patients with hemophilia A/B and congenital factor VII deficiency, an open-label, multicenter phase I/II clinical trial.